Alpha 2.0
Login Register
» Articles » PMID: 37503487

A 40-Year-Old Female With Mycobacterium Abscessus Successfully Treated With a Dual Beta-Lactam Combination

Overview
Journal Cureus
Specialty Biomedical Engineering
Date 2023 Jul 28
PMID 37503487
Authors
Natalia Moguillansky
Kathryn DeSear
Khalid M Dousa
Affiliations
Soon will be listed here.
Abstract

Nontuberculous mycobacteria (NTM) infections are difficult to treat conditions, specially  () lung disease. The most recent ATS/ERS/ESCMID/IDSA clinical practice guidelines (2020) recommend regimens of multiple intravenous (IV) and oral antibiotics. Recent in vitro studies on show that the combination of two beta-lactam antibiotics, as well as select beta-lactamase inhibitors, provides significant synergy in its treatment. We present the first in vivo case of the successful treatment of with imipenem and amoxicillin in addition to macrolides, clofazimine, and inhaled liposomal amikacin.

Citing Articles

Durlobactam in combination with β-lactams to combat .

Shin E, Dousa K, Taracila M, Bethel C, Nantongo M, Nguyen D Antimicrob Agents Chemother. 2024; 69(2):e0117424.

PMID: 39714147 PMC: 11823594. DOI: 10.1128/aac.01174-24.

Use of epigenetically modified bacteriophage and dual beta-lactams to treat a Mycobacterium abscessus sternal wound infection.

Cristinziano M, Shashkina E, Chen L, Xiao J, Miller M, Doligalski C Nat Commun. 2024; 15(1):10360.

PMID: 39609405 PMC: 11604996. DOI: 10.1038/s41467-024-54666-4.

The use of dual β-lactams to restore susceptibility of complex.

Al-Jabri M, Dousa K, Wilson B, Bonomo R JAC Antimicrob Resist. 2024; 6(5):dlae142.

PMID: 39281290 PMC: 11398912. DOI: 10.1093/jacamr/dlae142.

Case Commentary: Dual β-lactam as part of regimen to treat lung disease.

Lippincott C, Lamichhane G Antimicrob Agents Chemother. 2024; 68(7):e0058524.

PMID: 38837394 PMC: 11232395. DOI: 10.1128/aac.00585-24.

Dual β-lactam for treatment of pulmonary in a child.

Becken B, Dousa K, Johnson J, Holland S, Bonomo R Antimicrob Agents Chemother. 2024; 68(7):e0031924.

PMID: 38757973 PMC: 11232406. DOI: 10.1128/aac.00319-24.

References
1.
Han D, Lee K, Koh W, Yi C, Kim T, Kwon O . Radiographic and CT findings of nontuberculous mycobacterial pulmonary infection caused by Mycobacterium abscessus. AJR Am J Roentgenol. 2003; 181(2):513-7. DOI: 10.2214/ajr.181.2.1810513. View
2.
Prevots D, Marras T . Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015; 36(1):13-34. PMC: 4332564. DOI: 10.1016/j.ccm.2014.10.002. View
3.
Daley C, Iaccarino J, Lange C, Cambau E, Wallace Jr R, Andrejak C . Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020; 56(1). PMC: 8375621. DOI: 10.1183/13993003.00535-2020. View
4.
Lopeman R, Harrison J, Rathbone D, Desai M, Lambert P, Cox J . Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus. Sci Rep. 2020; 10(1):928. PMC: 6985242. DOI: 10.1038/s41598-020-57844-8. View
5.
Story-Roller E, Galanis C, Lamichhane G . β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates. Antimicrob Agents Chemother. 2020; 65(4). PMC: 8097488. DOI: 10.1128/AAC.02545-20. View